Clinical Study on Sepsis with Integrated Traditional Chinese and Western Medicine

注册号:

Registration number:

ITMCTR2000004173

最近更新日期:

Date of Last Refreshed on:

2020-12-17

注册时间:

Date of Registration:

2020-12-17

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

脓毒血症的中西医结合临床研究

Public title:

Clinical Study on Sepsis with Integrated Traditional Chinese and Western Medicine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

上海市重大危重医疗事件中西医协同响应与干预平台建设

Scientific title:

Construction of a collaborative response and intervention platform for Chinese and Western medicine in major and critical medical incidents in Shanghai

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000041067 ; ChiMCTR2000004173

申请注册联系人:

董青青

研究负责人:

陈伟

Applicant:

Qingqing Dong

Study leader:

Wei Chen

申请注册联系人电话:

Applicant telephone:

+86 16602152267

研究负责人电话:

Study leader's telephone:

+86 18917763057

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sixi16602152267@163.com

研究负责人电子邮件:

Study leader's E-mail:

cwdoctor@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宛平南路725号

研究负责人通讯地址:

上海市徐汇区宛平南路725号

Applicant address:

725 Wanping Road South, Xuhui District, Shanghai

Study leader's address:

725 Wanping Road South, Xuhui District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属龙华医院

Applicant's institution:

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020LCSY065

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海中医药大学附属龙华医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/9/24 0:00:00

伦理委员会联系人:

刘胜

Contact Name of the ethic committee:

Liu Sheng

伦理委员会联系地址:

上海市徐汇区宛平南路725号

Contact Address of the ethic committee:

725 Wanping Road South, Xuhui District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属龙华医院

Primary sponsor:

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市徐汇区宛平南路725号

Primary sponsor's address:

725 Wanping Road South, Xuhui District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

具体地址:

徐汇区宛平南路725号

Institution
hospital:

Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine

Address:

725 Wanping Road South, Xuhui District

经费或物资来源:

上海市重大危重医疗事件中西医协同响应与干预平台建设

Source(s) of funding:

Construction of a collaborative response and intervention platform for Chinese and Western medicine in major and critical medical incidents in Shanghai

研究疾病:

脓毒症

研究疾病代码:

Target disease:

Sepsis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

探讨中药的抗炎机制;同时通过对脓毒血症的中西医结合治疗,降低死亡率,缩短住院时间。

Objectives of Study:

Explore the anti-inflammatory mechanism of traditional Chinese medicine; at the same time, reduce the mortality rate and shorten the length of hospital stay through the combined treatment of Chinese and Western medicine for sepsis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合2016年脓毒症与脓毒性休克治疗指南Sepsis3.0诊断标准; 2.符合中医毒热内盛证、气阴耗伤证、瘀毒内阻证、阳气虚衰证辨证标准; 3.年龄18周岁~90周岁的患者; 4.已经签署知情同意书的患者。

Inclusion criteria

1. Meet the diagnostic criteria of Sepsis3.0 in 2016 guidelines for the treatment of sepsis and septic shock; 2. It conforms to the syndrome differentiation standards of TCM, such as the internal sheng syndrome of toxic heat, the syndrome of consumption of Qi and Yin, the syndrome of internal resistance of stasis, and the syndrome of deficiency and decline of Yang qi; 3. Patients aged between 18 and 90 years old; 4. Patients who have signed informed consent.

排除标准:

1.肺部肿瘤、肺结核所引起的肺部感染患者; 2.免疫系统严重抑制如艾滋病、肿瘤放化疗、风湿结缔组织病患者; 3.入院后24小时内死亡的患者; 4.对治疗所用药物有过敏史的患者; 5.妊娠、准备妊娠或哺乳期妇女; 6.有精神障碍患者; 7.无法服用中药的患者,无论是何种原因造成的; 8.各种原因禁食者

Exclusion criteria:

1. Patients with lung infections caused by lung tumors and tuberculosis; 2. Patients with severe immune system suppression such as AIDS, tumor radiotherapy and chemotherapy, rheumatic connective tissue disease; 3. Patients who died within 24 hours after admission; 4. Patients with a history of allergies to the drugs used for treatment; 5. Women who are pregnant, preparing to become pregnant or breast-feeding; 6. Patients with mental disorders; 7. Patients who are unable to take traditional Chinese medicine, regardless of the cause; 8. Fasting for various reasons.

研究实施时间:

Study execute time:

From 2021-01-01

To      2022-08-31

征募观察对象时间:

Recruiting time:

From 2021-01-01

To      2021-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

100

Group:

control group

Sample size:

干预措施:

西药标准治疗

干预措施代码:

Intervention:

Western medicine standard treatment

Intervention code:

组别:

试验组

样本量:

100

Group:

experimental group

Sample size:

干预措施:

西药标准治疗基础上加用中药浓煎剂,口服,一次100ml,一日1次。

干预措施代码:

Intervention:

On the basis of the standard treatment of western medicine, a concentrated decoction of traditional Chinese medicine is used, orally, 100ml once, once a day.

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

单位级别:

三甲

Institution/hospital:

Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肾功能

指标类型:

主要指标

Outcome:

Renal function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症因子

指标类型:

主要指标

Outcome:

Inflammatory factors

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

liver function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

外周血T淋巴细胞分型CD4+

指标类型:

主要指标

Outcome:

Peripheral blood T lymphocyte typing CD4 +

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子-α

指标类型:

主要指标

Outcome:

Tumor necrosis factor-α

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清C反应蛋白

指标类型:

主要指标

Outcome:

CRP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

外周血T淋巴细胞分型CD8+

指标类型:

主要指标

Outcome:

Types of peripheral blood T lymphocytesCD8+

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NK细胞百分比

指标类型:

主要指标

Outcome:

Percentage of NK cells

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清降钙素原

指标类型:

主要指标

Outcome:

PCT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用完全随机化分组,借助SPSS 21.0统计分析软件系统产生200个随机数字,再借助SPSS统计分析软件随机分为2组。

Randomization Procedure (please state who generates the random number sequence and by what method):

200 random numbers are generated by SPSS 21.0 statistical analysis software system. Then they are randomly divided into two groups by SPSS statistical analysis software.

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

依托学校及医院科研平台进行共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Sharing scientific research based on platform of schools and hospitals

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过手写记录及电子保存、整理、归纳,并按时填写患者病例报告表。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data by hand written records and electronic storage, sorting, induction, and on time to fill in patients with case report form.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above